Gilead Sciences (NASDAQ:GILD) Price Target Lowered to $145.00 at Barclays

Gilead Sciences (NASDAQ:GILD) had its target price decreased by equities research analysts at Barclays from $155.00 to $145.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Barclays‘s price objective would indicate a potential upside of 7.95% from the stock’s previous close.

GILD has been the topic of several other research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a research note on Monday, July 6th. Morgan Stanley reduced their price target on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research report on Monday. Leerink Partners lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Weiss Ratings lowered shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Finally, Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research note on Wednesday, May 20th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $157.93.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $134.32 on Wednesday. The business’s 50-day moving average price is $129.64 and its 200-day moving average price is $135.75. Gilead Sciences has a 12 month low of $108.46 and a 12 month high of $157.29. The firm has a market capitalization of $166.77 billion, a price-to-earnings ratio of 18.30 and a beta of 0.32. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the prior year, the firm posted $1.81 earnings per share. The firm’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts forecast that Gilead Sciences will post -0.77 EPS for the current year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the transaction, the insider directly owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the transaction, the chief executive officer owned 617,567 shares in the company, valued at $81,185,357.82. The trade was a 2.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 67,000 shares of company stock valued at $8,687,140. 0.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences in the fourth quarter valued at $25,000. Vermillion & White Wealth Management Group LLC boosted its position in shares of Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 85 shares in the last quarter. Quattro Advisors LLC bought a new position in shares of Gilead Sciences during the 4th quarter worth about $26,000. Wealth Preservation Advisors LLC grew its stake in shares of Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 81 shares during the period. Finally, Ares Financial Consulting LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at about $28,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Morgan Stanley maintained an “overweight” rating on Gilead and reduced its price target only slightly, from $166 to $165. The target still implies substantial upside from recent trading levels, reinforcing a favorable view of the company’s valuation and outlook. Benzinga analyst update
• Positive Sentiment: Gilead outperformed the broader stock market in the latest session. The reports did not identify a new company-specific catalyst, suggesting the move may reflect market positioning and investor interest in the large-cap biopharmaceutical sector rather than a major fundamental announcement. Gilead Sciences Laps the Stock Market
• Neutral Sentiment: Gilead’s upcoming results remain a key focus. Recent coverage highlights expectations for an earnings decline and suggests the company lacks the historical estimate-revision and earnings-surprise trends that typically support a strong beat. Investors may therefore look closely at product sales, guidance, and pipeline progress in the next report. Analysts Estimate Gilead to Report a Decline in Earnings
• Negative Sentiment: Erste Group Bank lowered its FY2027 EPS forecast for Gilead to $9.59 from $9.65. Although the reduction is small, it indicates slightly softer expectations for longer-term earnings growth and may weigh on sentiment at a time when investors are assessing the sustainability of Gilead’s earnings outlook.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.